Skip to content
    PVLA
    Earnings call· Jun 2026(Q2 FY26)

    PALVELLA THERAPEUTICS Q2 FY26 earnings call PVLA

    Aug 4, 2026 Source

    Executive summary

    Palvella Therapeutics Q2 FY26 — NDA Submission Progress and Pipeline Expansion

    Palvella Therapeutics made significant strides in Q2 FY26, advancing its lead asset, QTORIN rapamycin, towards FDA approval for microcystic lymphatic malformations (MLM) with the first NDA module submitted. The company is also expanding its pipeline across multiple rare skin diseases, leveraging its QTORIN platform and a strong cash position to invest in pre-launch activities and clinical development. Management remains focused on bringing first-in-disease therapies to patients with high unmet needs.

    Highlights

    5

    • Completed submission of the first module of the NDA for QTORIN rapamycin in microcystic lymphatic malformations (MLM), remaining on track for full submission in H2 2026 and potential FDA approval in H1 2027.

    • Achieved compelling safety and efficacy results from the Phase III SELVA study, with 95% of patients demonstrating improvement on the primary endpoint at week 24.

    • Strengthened balance sheet with approximately $251 million in cash at quarter-end, providing capital through potential FDA approval and commercial launch.

    • Expanded planned sales force at launch to approximately 40 sales reps, at the upper end of prior guidance, to strengthen field coverage and physician education.

    • Initiated Phase II LOTU study for QTORIN rapamycin in clinically significant angiokeratomas earlier than expected, with data anticipated in H2 2027.

    Concerns

    1

    • Breakthrough Therapy Designation for cutaneous venous malformations (cVM) was not granted based on initial 12-week data, though a resubmission is planned with 24-week data.

    Guidance & targets

    6
    CategoryTargetConfidence
    QTORIN rapamycin NDA submission (MLM)
    Complete NDA submission
    high materiality
    High
    QTORIN rapamycin FDA approval (MLM)
    Potential FDA approval
    high materiality
    High
    QTORIN rapamycin FDA approval (cVM)
    Potential FDA approval
    medium materiality
    Medium
    QTORIN rapamycin FDA approval (angiokeratomas)
    Potential FDA approval
    medium materiality
    Medium
    Fourth QTORIN rapamycin indication
    Announce fourth indication
    low materiality
    High
    Cash expenses
    $85M-$95M
    medium materiality
    High

    Operational metrics

    21
    Cash and investments balance
    $251M
    Q2 FY26

    Cash and investments balance at the end of the quarter, providing financial flexibility through potential FDA approval and commercial launch.

    Capital raise
    $230M
    Q1 FY26

    Amount raised in a successful financing completed in February, exceeding the original objective of $150 million.

    Original capital raise objective
    $150M
    Q1 FY26

    The initial objective for the capital raise, which was ultimately exceeded.

    Sales force size at launch
    40upper end of prior guidance
    Launch

    Increased planned sales force to strengthen field coverage, physician education, patient identification, and access support.

    MLM diagnosed patients (conservative estimate)
    >30,000
    Current

    Conservative estimate of diagnosed microcystic lymphatic malformations patients in the U.S., based on data-driven epidemiological work.

    MLM diagnosed patients (claims analysis range)
    45,000-95,000
    Current

    Range of diagnosed microcystic lymphatic malformations patients in the U.S. based on a claims analysis published at a medical congress.

    MLM annual incidence
    1,500+
    Annual

    Estimated annual incidence of newly diagnosed microcystic lymphatic malformations patients.

    cVM diagnosed patients (conservative estimate)
    >75,000
    Current

    Conservative estimate of diagnosed cutaneous venous malformations patients in the U.S.

    cVM diagnosed patients (literature estimate)
    135,000
    Current

    Estimate of diagnosed cutaneous venous malformations patients in the U.S. from a recent publication in Orphanet Journal of Rare Diseases.

    Angiokeratomas diagnosed patients
    >50,000
    Current

    Estimated diagnosed patients with clinically significant angiokeratomas in the U.S.

    DSAP diagnosed patients
    >50,000
    Current

    Estimated diagnosed patients with disseminated superficial actinic porokeratosis in the U.S.

    Total addressable patient population (QTORIN rapamycin)
    >300,000
    Future

    Potential expansion of QTORIN rapamycin's addressable U.S. patient population across multiple mTOR-driven indications from >30,000 in MLM.

    Physician consideration for QTORIN product (first-line)
    >80%
    Current

    Percentage of physicians surveyed who indicated they would consider the QTORIN product candidate as a first-line therapy, if approved, across all four indications.

    Physician intent to incorporate QTORIN rapamycin (angiokeratomas)
    96%
    Current

    Percentage of surveyed physicians who indicated they would incorporate QTORIN rapamycin into their practice for angiokeratomas.

    MLM patients seeking treatment
    60%
    Current

    Percentage of MLM patients managed by DSAPs who are actively seeking treatment for their MLM, according to a physician survey.

    MLM mLM-IGA improvement (children 6-11)
    2.46
    Week 24

    Mean mLM-IGA improvement observed in children aged 6 to 11 in the Phase III SELVA study.

    MLM mLM-MCSS improvement
    3.448% of maximum potential improvement from baseline
    Week 24

    Blinded mean mLM-MCSS improvement after 24 weeks of treatment with QTORIN rapamycin.

    cVM cVM-IGA improvement
    73%more than twice predefined success threshold
    Phase II

    Percentage of patients who improved on the cVM-IGA in the Phase II TOIVA study.

    MLM pricing range
    $100,000-$200,000
    Launch

    Guided pricing range for QTORIN rapamycin in microcystic lymphatic malformations, with strong payer coverage expected.

    Target clinics engaged
    200of initial 400 target clinics
    Current

    Number of initial target clinics engaged as part of pre-launch activities.

    MLM patients under management in target centers
    15,000+
    Current

    Estimated number of MLM patients under management in the top 400 high-volume centers.

    Industry KPIs

    4
    MetricValueDetails
    Launch access metricsStrong outlook
    Pipeline read out calendarMultiple programs
    Regulatory approvals filingsMLM NDA first module submitted
    Clinical trial efficacy safety data95% patients improved%

    Risks & headwinds

    1
    Breakthrough Therapy Designation for cVM not granted

    Initial request based on 12-week data was not granted

    Mitigation: Plan to resubmit with complete 24-week efficacy data set and final Phase II qualitative report after upcoming FDA interaction and Phase III initiation.

    What to watch in Q3 FY26

    4

    QTORIN rapamycin NDA submission

    H2 FY26
    CurrentFirst module submitted
    TargetFull NDA submission completed

    Why it matters

    Completion of the NDA submission is a critical step towards potential FDA approval and commercialization of the lead asset.

    I am pleased to report today that, #1, we remain on track to complete our NDA submission in the second half of this year.

    Q&A highlights

    5

    Can you elaborate on efforts to identify MLM patients and confirm if recent findings align with the initial estimate of ~30,000 diagnosed patients?

    Recent findings confirm the estimate of greater than 30,000 diagnosed MLM patients in the U.S., with an estimated annual incidence of 1,500+ new diagnoses. Patient identification focuses on high-volume vascular anomaly centers and physicians, supported by strong presence at medical congresses.

    “I can confirm that our recent findings are in line with previous estimates. Last year, we published a claims analysis at a medical congress that indicated somewhere between 45,000 and 95,000 diagnosed MLM patients in the U.S. Importantly, in that analysis that's published, there was also an estimated annual incidence of 1,500 or more newly diagnosed patients that will come into that pool.”

    asked by Alexa Deemer · answered by Wesley Kaupinen

    2 min read6 chapters

    Detailed Narrative

    01

    NDA Progress for Microcystic Lymphatic Malformations (MLM)

    Palvella achieved significant milestones for QTORIN rapamycin in MLM, including a pre-NDA meeting with the FDA, granted rolling review status, and the submission of the first module of its NDA. The company remains on track to complete the full NDA submission in the second half of 2026 and anticipates potential FDA approval in the first half of 2027. The application is supported by Breakthrough Therapy, Fast Track, and Orphan Drug Designations, leveraging the 505(b)(2) regulatory pathway.

    02

    Pipeline-in-a-Product Strategy and Market Opportunity

    QTORIN rapamycin is being developed as a pipeline-in-a-product, targeting multiple rare diseases driven by mTOR signaling. The strategy aims to expand the addressable U.S. patient population from over 30,000 in MLM to over 300,000 across multiple indications, including cutaneous venous malformations (cVM) and clinically significant angiokeratomas. Palvella focuses on diseases with no FDA-approved treatments and multi-billion dollar total addressable markets, based on data-driven epidemiological work.

    03

    Launch Readiness and Commercial Investments

    Palvella is actively preparing for the potential U.S. launch of QTORIN rapamycin, having assembled a leadership team with deep rare disease and dermatology experience. Key pre-launch activities include engaging target clinics, building patient services infrastructure, and conducting payer research. The company has increased its planned sales force to approximately 40 reps and is making additional investments in medical affairs and marketing to ensure a successful launch and efficient patient access.

    04

    Clinical Data and Therapeutic Profile of QTORIN Rapamycin

    The Phase III SELVA study for MLM demonstrated highly compelling results, with 95% of patients showing improvement on the primary endpoint and a favorable safety profile. New analysis in children aged 6-11 showed a rapid, large-magnitude treatment effect, with every child rated as much or very much improved. The innovative trial design, including an 8-week untreated run-in period, objectively confirmed that observed improvements resulted from QTORIN rapamycin treatment.

    05

    Advancement of Cutaneous Venous Malformations (cVM) Program

    The Phase II TOIVA study for cVM showed 73% of patients improved on the cVM-IGA, exceeding the predefined success threshold. Palvella plans to initiate a Phase III study in Q4 2026, following an End of Phase II meeting with the FDA to finalize the pivotal study design. Despite not receiving Breakthrough Therapy Designation initially, the company plans a resubmission with complete 24-week efficacy data and qualitative patient reports.

    06

    Progress in Angiokeratomas and DSAP Programs

    The Phase II LOTU study for clinically significant angiokeratomas, a natural extension of the QTORIN rapamycin strategy, has dosed its first patients ahead of schedule, with data expected in H2 2027. This program is expected to follow a supplemental NDA pathway. For disseminated superficial actinic porokeratosis (DSAP), the QTORIN pitavastatin program remains on track for Phase II initiation in Q4 2026, targeting a chronic, precancerous skin disease with high unmet need.

    AI-generated summary of the company’s earnings call. Not investment advice.